KD Logo

Halozyme Therapeutics Inc. [NASDAQ: HALO] Sees Increase in Stock Value

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Halozyme Therapeutics Inc. shares valued at $520,400 were sold by LaBrosse Nicole on Jun 28 ’24. At $52.04 per share, LaBrosse Nicole sold 10,000 shares. The insider’s holdings dropped to 15,480 shares worth approximately $0.83 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Also, LaBrosse Nicole sold 10,000 shares, netting a total of over 519,340 in proceeds. Following the sale of shares at $51.93 each, the insider now holds 15,480 shares.

Before that, LaBrosse Nicole had sold 10,000 shares from its account. In a trade valued at $518,200, the SVP, CHIEF FINANCIAL OFFICER traded Halozyme Therapeutics Inc. shares for $51.82 each. Upon closing the transaction, the insider’s holdings decreased to 10,000 shares, worth approximately $0.83 million.

As published in a research note from Piper Sandler on June 07, 2024, Halozyme Therapeutics Inc. [HALO] has been rated down from an Overweight to a Neutral and the price target has been revised to $51 from $48. Analysts at TD Cowen started covering the stock with ‘”an Outperform”‘ outlook in a report released in late February. As of July 24, 2023, H.C. Wainwright has initiated its “Buy” rating for HALO. Earlier on July 24, 2023, Goldman downgraded its rating. Their new recommendation was “a Neutral” for HALO stock which previously was a “a Buy”.

Analyzing HALO Stock Performance

During the last five days, there has been a surge of approximately 2.77%. Over the course of the year, Halozyme Therapeutics Inc. shares have jumped approximately 44.59%. Shares of the company reached a 52-week high of $53.22 on 07/01/24 and a 52-week low of $33.15 on 02/05/24. A 50-day SMA is recorded $45.76, while a 200-day SMA reached $39.84. Nevertheless, trading volume fell to 0.84 million shares from 1.04 million shares the previous day.

Support And Resistance Levels for Halozyme Therapeutics Inc. (HALO)

According to the 24-hour chart, there is a support level at 51.15, which, if violated, would cause prices to drop to 50.30. In the upper region, resistance lies at 52.64. The next price resistance is at 53.27. RSI (Relative Strength Index) is 70.47 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.55, which suggests the price will decrease in the coming days. Percent R is at 24.35%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.

Most Popular